Natco Pharma Stock Drops Following USFDA's 7 Observations at Chennai API Plant
Loading more articles...
Natco Pharma Shares Dip After USFDA Issues 7 Observations for Chennai Unit
C
CNBC TV18•13-02-2026, 10:28
Natco Pharma Shares Dip After USFDA Issues 7 Observations for Chennai Unit
•Natco Pharma shares declined after the USFDA issued seven observations under Form 483 for its Chennai API unit.
•The USFDA inspected the active pharmaceutical ingredient (API) division unit in Manali, Chennai, from November 17 to November 21, 2025.
•The inspection was classified as Voluntary Action Indicated (VAI) in the establishment inspection report (EIR).
•Despite the decline, the company recently reported a 14.3% increase in consolidated net profit to ₹152 crore and a 36.3% rise in revenue to ₹647.3 crore.
•Natco Pharma's EBITDA surged to ₹158.7 crore, with its EBITDA margin improving to 24.5%.
